Valuation: Personalis, Inc.

Market Cap 1.71B 1.53B 1.41B 1.28B 2.42B 160B 2.48B 16.82B 6.7B 85.9B 6.42B 6.29B 271B P/E 2026 *
-13x
P/E 2027 * -16.4x
Enterprise Value 1.71B 1.53B 1.41B 1.28B 2.42B 160B 2.48B 16.82B 6.7B 85.9B 6.42B 6.29B 271B EV / Sales 2026 *
19x
EV / Sales 2027 * 15.5x
Free-Float
74.4%
Yield 2026 *
-
Yield 2027 * -
1 day+1.01%
1 week+1.21%
Current month+0.82%
1 month-0.31%
3 months+10.00%
6 months+175.95%
Current year+100.38%
1 week 15.52
Extreme 15.52
16
1 month 15.5
Extreme 15.505
16.17
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
19.65
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 58 02/03/2023
Chief Executive Officer 66 31/12/2022
President 56 13/03/2026
Director TitleAgeSince
Director/Board Member 80 01/05/2019
Director/Board Member 73 14/06/2023
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Sell

Chief Financial Officer

-2,931 0.0028%
18/9/26 Sell

Chairperson

-3,998 0.0038%
18/9/26 Sell

Chief Executive Officer

-7,459 0.0071%
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%+1.21%+84.82%+1,596.81% 1.71B
+1.67%-3.68%+9.94%+27.73% 107B
+2.00%+7.94%+9.93%+121.87% 103B
+3.13%-15.45%+55.05%+605.86% 45.05B
+0.21%+9.80%+10.16%+103.96% 32.96B
+1.43%+4.57%+42.39%+82.02% 29.77B
+1.58%+3.53%+40.89%+97.26% 28.12B
+2.00%+7.48%+48.45%+448.80% 22.55B
-0.37%+0.09%-19.78%-19.41% 20.05B
-0.26%-1.91%-7.00%+28.33% 16.76B
Average +1.24%-1.63%+27.49%+309.32% 40.76B
Weighted average by Cap. +1.61%-2.55%+19.73%+158.01%

Financials

2026 *2027 *
Net sales 90.2M 80.51M 74.09M 67.24M 127M 8.45B 131M 886M 353M 4.53B 339M 331M 14.26B 110M 98.29M 90.44M 82.09M 156M 10.32B 159M 1.08B 431M 5.53B 413M 404M 17.4B
Net income -129M -115M -106M -96.24M -182M -12.1B -187M -1.27B -506M -6.48B -485M -474M -20.4B -103M -92.13M -84.78M -76.95M -146M -9.68B -149M -1.01B -404M -5.18B -387M -379M -16.31B
Net Debt - -
Projected Income Statement - Annual - Personalis, Inc.
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
10/11/26 USD 15.95 +1.01% 2,323,917
06/11/26 USD 15.79 +1.54% 3,000,201
05/11/26 USD 15.55 -1.52% 3,788,458
04/11/26 USD 15.79 +0.25% 2,217,753
03/11/26 USD 15.75 -0.06% 2,930,167
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Personalis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
15.79USD
Average target price
15.17USD
Spread / Average Target
-3.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Personalis, Inc.
  1. Stock Market
  2. Stocks
  3. PSNL Stock